7.28
Penn in the News
A round-up of Penn mentions in local, national, and international media.
Filter Stories
Displaying 71 - 80 of 9248
Penn In the News
What won’t the infrastructure plan do? Repair our crumbling schools
Nell Williams, a Ph.D. student in the Graduate School of Education, wrote an op-ed in support of the Biden administration’s infrastructure plan, which allocates funds to repair school buildings. “As the infrastructure plan undergoes further negotiation in the House and Senate, I urge policymakers note the gaping hole that was left when most U.S. schools went virtual last year,” she said.
Penn In the News
The controversial approval of an Alzheimer’s drug reignites the battle over the underlying cause of the disease
Jason Karlawish of the Perelman School of Medicine spoke about the ramifications of the FDA’s approval of Aduhelm, an Alzheimer’s drug. “One of the consequences is that other companies will say, ‘If this is your new lower bar, we want our drugs approved on that basis,’” he said. “Companies are companies, I can’t fault them for doing what companies do, but we have now unleashed drugs that we are not sure what the benefits are, and that could have enormous consequences.”
Penn In the News
The number of Philly high school students who are homeless may be four times higher than what’s been reported
Dan Treglia of the School of Social Policy & Practice co-authored a report about homelessness among high school students. The survey corrects for the U.S. Department of Housing and Urban Development’s tally of those living in shelters and on the street, which Treglia says misses homeless high schoolers who are staying with friends.
Penn In the News
Racial differences in COVID mortality rates linked to unequal hospital quality, Penn study shows
David Asch and Rachel Werner of the Leonard Davis Institute co-authored research that found disparities between COVID-19 outcomes based on which hospital a patient was admitted to. “Patients tend to go to hospitals that are near them, and therefore Black patients are more likely to go to hospitals that are underresourced,” said Asch. “It’s a story of inequity, it’s a story of structural racism that has its origins centuries in the past.”
Penn In the News
Penn finds a surprising benefit to wisdom tooth surgery: better taste
Research by Richard Doty of the Perelman School of Medicine and Dane Kim, a student in the School of Dental Medicine, found that people who have had wisdom teeth removed had a slightly stronger sense of taste over time. Earlier studies have focused on the temporary loss of taste associated with the procedure.
Penn In the News
A mysterious illness is killing Mid-Atlantic songbirds
Lisa Murphy of the School of Veterinary Medicine spoke about the Wildlife Futures Program’s research on the illness killing songbirds in the Mid-Atlantic region. "I think what's especially challenging about this is that it's not localized ... to one specific geographic area [and] it's not localized to one particular bird species,” she said.
Penn In the News
Lawmakers are under pressure to take on Big Tech
PIK Professor Herbert Hovenkamp weighed in on a pair of legal rulings that dismissed antitrust lawsuits against Facebook. “This is going to strengthen the case for legislation,” he said. “It seems to be proof that the antitrust laws are not up to the challenge.”
Penn In the News
Penn doctor on his award-winning short film to improve awareness of stroke
Renyu Liu of the Perelman School of Medicine directed a short film to improve awareness of stroke symptoms. “We are trying to improve stroke awareness by removing the barrier of languages across the world,” he said.
Penn In the News
Column: Walmart’s low-priced insulin shows what a rational drug market should look like
Mark V. Pauly of the Wharton School weighed in on Walmart’s new, lower cost insulin. The offering “may be a PR or traffic-building exercise,” he said, but could ultimately pressure drug companies to lower their prices.
Penn In the News
CureVac, the latest experimental coronavirus vaccine, proves just 48 percent effective overall, a disappointing result
Drew Weissman of the Perelman School of Medicine responded to claims by CureVac executives that their COVID-19 vaccine’s poor results were due to the number of variants, among other factors. “Variants may account for some of their poor efficacy, but the modified [messenger RNA] vaccines have shown good efficacy against variants,” said Weissman.